NOV 17, 202656 MINS READ
Creatine phosphate (N-(alpha-imino-alpha-phosphonamido)-methyl-N-methylglycine, chemical formula C₄H₁₀N₃O₅P) exists in multiple hydration states depending on crystallization conditions 4,6. The disodium salt of phosphocreatine commonly crystallizes with 4–6 molecules of water (Na₂·C₄H₈N₃O₅P·4H₂O or ·6H₂O), while the potassium salt typically forms dihydrate or tetrahydrate structures (K₂·C₄H₈N₃O₅P·2H₂O) 4. The barium salt crystallizes as a monohydrate, and the lithium salt is anhydrous 4. These hydration differences critically influence solubility, thermal stability, and downstream formulation compatibility.
The phosphocreatine molecule comprises a guanidinium moiety, a carboxymethyl group, and a phosphate ester linkage. In aqueous solution, the phosphate group (pKa ~4.5) is fully ionized at physiological pH, conferring high polarity and water solubility to the anhydrous form (>200 g/L at 25°C) 2. However, the monohydrate form exhibits significantly lower solubility (~30 g/L at 25°C), a thermodynamic property exploited in purification workflows 2,8. The negative free enthalpy of hydration (ΔG_hyd ≈ −15 kJ/mol) drives spontaneous conversion of anhydrous creatine phosphate to the monohydrate in saturated aqueous media, providing the thermodynamic basis for crystallization-based purification 2.
Structural analysis by X-ray diffraction reveals that creatine phosphate monohydrate adopts a triclinic crystal system with space group P1̄, exhibiting well-defined (010) and (110) facets 1. Scanning electron microscopy (SEM) of sodium creatine phosphate crystals prepared via acetone-induced precipitation shows prismatic morphology with primary particle size distributions centered at 67.1–70.2 μm and aspect ratios of 2.5–3.5 1. The crystallographic habit is sensitive to supersaturation rate, solvent polarity, and the presence of seed crystals, all of which must be controlled to avoid dendritic growth or amorphous precipitation 2,9.
Industrial synthesis of creatine phosphate typically follows enzymatic or chemical phosphorylation routes. The enzymatic route employs creatine kinase (CK) to catalyze the transfer of a phosphoryl group from adenosine triphosphate (ATP) to creatine in the presence of Mg²⁺ ions 9. A representative protocol involves dissolving 260 g creatine in 100 L water, adding 15 g ATP·Na₂H₂·3H₂O (~12 g ATP), 380 g 3-phosphoglyceric acid sodium salt, 14 g magnesium acetate, 17 g potassium acetate, and 80 g ammonium acetate, adjusting pH to 8.5 with NaOH, and incubating at 37°C for 1–3 hours with a muscle extract containing 80,000 U creatine phosphokinase, 100,000 U enolase, 100,000 U phosphoglycerate mutase, and 250,000 U pyruvate kinase 9. The reaction mixture is then heated to 80–90°C to denature enzymes, filtered, and passed through a sodium-form cation exchanger (e.g., Amberlite IR-120 or Dowex 50) equilibrated to pH 8–9 9. The eluate is concentrated to 4–6 L, and 8–12 L ethanol is added under stirring until turbidity appears; seeding with crystalline sodium creatine phosphate initiates nucleation, and overnight storage at 4°C yields 300–350 g of Na₂·C₄H₈N₃O₅P·6H₂O with a molar yield of 60–70% 9.
Chemical synthesis routes include phosphorylation of creatine with phosphoryl chloride (POCl₃), phosphorus pentoxide (P₂O₅), or chlorophosphonic acid (ClPO₃H₂) under controlled pH and temperature 3,5,6. For example, creatinol sulfate is first protected by reaction with sulfuric acid, then treated with POCl₃ at 20–30°C for 1–3 hours, followed by hydrolysis with water (0.5–1 hour) to yield creatinol O-phosphate 3,5. The crude product is vacuum-filtered, washed with butanone until the eluate is colorless, and dried to afford creatinol O-phosphate with 60–85% yield and 92.55% purity 3. Recrystallization from water (5 g product in 30–50 mL water at 50–70°C, cooling to room temperature for 2–4 hours) elevates purity to 99.05% with 70–80% recovery 3,5. The melting point of purified creatinol O-phosphate is 243–244°C, confirming structural integrity 3,5.
Alternative phosphorylation methods employ dibenzyl phosphorochloridate or diphenyl phosphorochloridate as phosphorylating agents, followed by hydrogenolysis to remove protecting groups 6. These routes are advantageous for laboratory-scale synthesis but are less economical for industrial production due to the cost of protecting reagents and the need for catalytic hydrogenation 6.
Creatine phosphate crystallization is most commonly achieved by anti-solvent addition to aqueous solutions. Ethanol, methanol, acetone, and isopropanol are the preferred anti-solvents due to their miscibility with water and ability to reduce phosphocreatine solubility without inducing oiling-out 1,4,9,10. A representative protocol for sodium creatine phosphate involves dissolving crude product (0.5–1.1 g/mL) in water at 20–30°C, adding 1–2 wt% activated carbon, stirring for 30–60 minutes for decolorization, filtering, and transferring the filtrate to a crystallizer maintained at 5–45°C 1. Acetone is then added dropwise over 2 hours at a volumetric ratio of 2:1 (acetone:water), inducing precipitation of Na₂·C₄H₈N₃O₅P·6H₂O crystals 1. The slurry is filtered, washed with acetone, and dried at 40°C under 0.008 MPa absolute pressure for 4 hours, yielding product with 99.61% HPLC purity, 69.28 μm median particle size, and 98.0% single-pass molar recovery 1.
For potassium creatine phosphate, a similar workflow is employed, but methanol (5:1 volumetric ratio to water) is added over 5 hours at 10°C, and the filter cake is washed with ethanol before drying at 60°C under 0.008 MPa 1. The choice of anti-solvent and its addition rate critically influence crystal habit: rapid addition (>5 mL/min per 100 mL solution) promotes uncontrolled nucleation and fine, agglomerated crystals, whereas slow addition (<2 mL/min) favors growth on existing nuclei and yields larger, more uniform crystals 2,9.
Spontaneous nucleation of creatine phosphate monohydrate from supersaturated aqueous solutions often exhibits a metastable zone width (MSZW) of 5–10°C, leading to delayed crystallization and potential inclusion of mother liquor impurities 2. To circumvent this, seeding with creatine phosphate monohydrate crystals (1–10 wt% relative to solution mass, median size <100 μm) is introduced at the onset of supersaturation 2,9. Seeding abolishes the induction period and ensures heterogeneous nucleation, resulting in crystals with lower impurity entrapment and narrower size distributions 2.
In a batch crystallization protocol, creatine phosphate monohydrate seed crystals are suspended in a saturated aqueous solution at 25°C, and crude anhydrous creatine phosphate is added incrementally 2. The exothermic hydration reaction (ΔH_hyd ≈ −8 kJ/mol) raises the local temperature by 2–3°C, which must be compensated by external cooling to maintain isothermal conditions and prevent secondary nucleation 2. The crystal growth rate is maintained at <10 μm/min (preferably 5 μm/min) to minimize co-crystallization of arsenic, chromium, vanadium, and iron impurities, which are isomorphous with phosphorus and can substitute into the lattice at high supersaturation 2,11.
For continuous crystallization in a stirred-tank cascade, the first-stage crystallizer operates at 32–42°C with a residence time of 20–40 minutes, yielding primary crystals that are centrifuged and melted for feed to a second-stage recrystallizer at 37–47°C 1,13. The mother liquor from the second stage is recycled to the first stage, and the final product (P₂O₅ concentration 65–75 wt%) is dried and packaged 13. This multi-stage approach reduces impurity carryover by a factor of 10–100 relative to single-stage crystallization 10,13.
Post-crystallization washing is essential to remove residual mother liquor adhering to crystal surfaces. Unsaturated mother liquor from a subsequent recrystallization stage, heated 5°C above saturation temperature, is used as the wash liquid to prevent crystal dissolution 11. Alternatively, the wash liquid is prepared by dissolving product crystals in water to slight undersaturation 9,10. Washing is performed on a Buchner funnel or centrifuge filter, with wash volumes of 2–5 times the crystal bed volume 1,9,10. For sodium creatine phosphate, acetone or ethanol washing (3× bed volume) is sufficient to reduce residual impurities (creatine, ATP, ADP) to <0.1 wt% 1,10.
Drying is conducted under vacuum (0.008–0.05 MPa absolute pressure) at 40–60°C for 4–8 hours to remove residual solvent and achieve a final water content of 10–15 wt% (corresponding to the hexahydrate stoichiometry) 1,9,10. Over-drying (>70°C or >12 hours) can induce partial dehydration to lower hydrates or anhydrous forms, which are hygroscopic and prone to caking during storage 4.
Crude creatine phosphate solutions often contain colored impurities (e.g., Maillard reaction products, residual enzymes, or organic degradation products) that must be removed to meet pharmaceutical specifications 1,10. Activated carbon (1–2 wt% relative to creatine phosphate mass) is added to the aqueous solution at 20–30°C and stirred for 30–60 minutes 1. The carbon is then removed by filtration through a 0.45 μm membrane or a bed of diatomaceous earth 1,10. This treatment reduces UV absorbance at 280 nm by 80–95% and improves the visual appearance of the final crystals 1.
For high-purity applications (e.g., injectable formulations), ion-exchange chromatography is employed to remove creatine, ATP, ADP, and metal cations 10. The crude creatine phosphate solution is first pre-treated with 40–70 vol% ethanol to precipitate high-molecular-weight impurities, then loaded onto a strong anion-exchange resin (e.g., Dowex 1 or Amberlite IRA-400 in Cl⁻ form) at a flow rate of 1–2 bed volumes per hour (BV/h) 10. Creatine and nucleotides are eluted with 0.02–0.15 M NaCl at 2–4 BV/h, and creatine phosphate is subsequently eluted with 0.2–0.8 M NaCl (preferably 0.4 M) at 4 BV/h 10. The eluate is concentrated to >30 mg/mL, and 80 vol% ethanol is added at 15–20°C to induce crystallization over 24–48 hours 10. This protocol achieves 99.80% purity and 40% overall recovery 10.
Multi-stage recrystallization is the gold standard for achieving pharmaceutical-grade purity (>99.5%) 2,3,5,11. In a typical two-stage process, primary crystals (92–95% purity) are dissolved in water at 50–70°C to form a saturated solution, which is then cooled to room temperature over 2–4 hours to induce secondary crystallization 3,5. The crystals are vacuum-filtered, washed with cold water or dilute ethanol, and dried 3,5. This cycle is repeated if necessary to reach 99.05–99.61% purity 1,3,5.
Sweating (controlled partial melting) is an advanced purification technique applicable to melt-crystallized creatine phosphate 11,13. Crystals are heated to 1–3°C below their melting point (e.g., 85–87°C for the hexahydrate) for 10–30 minutes, allowing impurity-rich eutectic phases to melt and drain away while the bulk crystal remains solid 11. The sweated crystals are then fully melted and recrystallized, yielding product with <10 ppm total metal impurities and <0.01% organic impurities 11,13.
Creatine phosphate is administered intravenously or intramuscularly at daily doses of 200–400 mg to treat myocardial ischemia, degenerative cardiomyopathies, and post-infarction contractility deficits 12. The active pharmaceutical ingredient (API) must meet stringent purity criteria: ≥99.0% assay, ≤0.1% creatine, ≤0.05% inorganic phosphate, ≤10 ppm heavy metals, and ≤0.5 EU/mg endotoxin 12. Crystallization-based purification, particularly when combined with ion-exchange chromatography and recrystallization, reliably achieves these specifications 1,10,12. The crystalline form (typically the disodium hexahydrate) is non-hygroscopic, stable at room temperature for >2 years, and readily soluble in sterile water for injection (>200 mg/mL) 4,12.
Creatine phosphate and its analogs (e.g., cyclocreatine phosphate) are investigated as ergogenic aids to enhance ATP regeneration in skeletal muscle during high-intensity exercise 15. Cyclocreatine phosphate (C₅H₈N₃O₅P·Na₂·3H₂O) exhibits improved aqueous solubility
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| TIANJIN UNIVERSITY | Industrial-scale pharmaceutical manufacturing of high-purity sodium creatine phosphate for injectable formulations in myocardial protection and muscular dystrophy treatment. | Sodium Creatine Phosphate Crystallization Process | Achieved 99.61% HPLC purity with 98.0% single-pass molar recovery, uniform particle size distribution (67.1-70.2 μm median), and complete crystal habit through acetone anti-solvent crystallization at controlled temperature (5-45°C). |
| BASF AKTIENGESELLSCHAFT | Pharmaceutical-grade creatine purification for nutritional supplements and therapeutic applications requiring stringent purity specifications (≤0.1% creatine, ≤10 ppm heavy metals). | Creatine Monohydrate Purification Technology | Utilized thermodynamic hydration driving force (negative free enthalpy ΔG ≈ -15 kJ/mol) with seeded crystallization to eliminate metastable zone delays, achieving >99.5% purity while controlling crystal size and minimizing impurity inclusion through controlled supersaturation. |
| TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD. | Laboratory and small-scale pharmaceutical production of creatinol O-phosphate for energy metabolism research and therapeutic formulations. | Creatinol O-Phosphate Synthesis & Recrystallization | Chemical phosphorylation route with POCl3 yielding 60-85% crude product (92.55% purity), followed by water recrystallization (50-70°C) elevating purity to 99.05% with 70-80% recovery and melting point 243-244°C. |
| XINAN PHARMACEUTICAL CO. LTD. | High-purity pharmaceutical-grade creatine phosphate production for injectable formulations meeting stringent regulatory requirements (≤0.5 EU/mg endotoxin, ≤10 ppm heavy metals). | Ion-Exchange Chromatography Purification System | Combined ethanol pre-treatment (40-70 vol%) with anion-exchange resin (0.4M NaCl elution at 4 BV/h) and 80 vol% ethanol crystallization at 15-20°C, achieving 99.80% purity with 40% overall recovery and removal of creatine/ATP/ADP impurities to <0.1 wt%. |
| BOEHRINGER MANNHEIM GMBH. | Industrial-scale biocatalytic production of pharmaceutical-grade sodium creatine phosphate for myocardial protection therapies and muscular dystrophy treatment requiring daily doses of 200-400 mg. | Enzymatic Creatine Phosphate Synthesis Process | Enzymatic phosphorylation using creatine kinase (80,000 U), enolase (100,000 U), and pyruvate kinase (250,000 U) at pH 8.5 and 37°C, followed by cation exchange and ethanol crystallization, yielding 300-350 g Na₂·C₄H₈N₃O₅P·6H₂O with 60-70% molar yield. |